Enrique Zudaire
Janssen R&D
Panama
Panama
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
Journal: The New England journal of medicine
Published: June 05, 2023
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.
Journal: Journal for immunotherapy of cancer
Published: March 30, 2023
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: March 21, 2023
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 06, 2022
Cancer cell survival depends on collagen uptake into tumor-associated stroma.
Journal: Nature communications
Published: March 18, 2022
Comprehensive BCMA Expression Profiling in Adult Normal Human Brain Suggests a Low Risk of On-target Neurotoxicity in BCMA-targeting Multiple Myeloma Therapy.
Journal: The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
Published: February 23, 2022
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.
Journal: Cancer chemotherapy and pharmacology
Published: September 21, 2021
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.
Journal: Blood cancer journal
Published: September 15, 2021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Journal: Lancet (London, England)
Published: February 18, 2021
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer.
Journal: Prostate cancer and prostatic diseases
Published: December 14, 2020
JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes-Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies.
Journal: JTO clinical and research reports
Published: August 04, 2020
Last Updated: 09/26/2026